secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001437749-25-015517
Event type: earnings
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set
--------------------------------------------------------------------------------

- GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.
- Cash and equivalents $119.3M as of March 31, 2025, down from $118.0M at Dec 31, 2024.
- Costs and expenses $18.0M, up $7.4M YoY, driven by stock-based comp and organization expansion.
- On track to launch nsPFA Percutaneous Electrode System in H2 2025; U.S. IDE for cardiac surgery and catheter systems expected mid-2025.
- Treated 100 patients in Europe with nsPFA 360° catheter; data presented at HRS 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/0001437749-25-015517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/plse20250506_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-015517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer